Nintedanib for Mesothelioma

Fact Checked

Nintedanib shows promise as an addition to the standard chemotherapy regimen for pleural mesothelioma. The drug is already approved for treating pulmonary fibrosis, and it is being tested in clinical trials for mesothelioma. Nintedanib is marketed under the brand name Ofev.

The U.S. Food and Drug Administration (FDA) first approved nintedanib (Ofev) in 2014 as a treatment for progressive lung scarring. In Europe, a version of the drug named Vargatef was also approved for use in chemotherapy for lung cancer.

In 2016, the FDA granted Ofev orphan drug designation for mesothelioma in response to promising phase II clinical trial results.

This designation encourages drug development for rare diseases. Other clinical trials of Ofev for mesothelioma are ongoing.

How Does Ofev Work?

Ofev blocks tyrosine kinase, a type of enzyme that triggers scar-tissue growth and blood-vessel development.

Blocking tyrosine kinase also reduces tumor growth and promotes tumor-cell death in certain types of cancer.

Ofev is approved in the U.S. to treat idiopathic pulmonary fibrosis, a disease where scarring in the lungs makes it progressively harder to breathe. The drug can slow down the buildup of scar tissue in the lungs.

Asbestosis is a type of pulmonary fibrosis, so Ofev is a potential treatment for asbestosis.

A 2018 Clinical Cancer Research study explains how Ofev may be effective against malignant pleural mesothelioma as well.

Laboratory experiments showed Ofev inhibits mesothelioma cell growth and prevents tumors from growing their own blood vessels. The study results suggested Ofev may work better than bevacizumab, a similar drug being tested in mesothelioma chemotherapy.

Ofev Information
Name Ofev
Alternate names Nintedanib, Vargatef
Manufacturer Boehringer Ingelheim
Dosage 200 mg twice daily
Administration Route Oral
Active Ingredient Nintedanib
Drug Class Tyrosine Kinase inhibitor
Medical Code BIBF 1120
Related Drug Pirfenidone
Interacting Drug Erythromycin, rifampicin, carbamazepine, phenytoin, St. John’s wort, warfarin, carbamazepine
Medical Studies Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
FDA Warning Liver problems, gastrointestinal disorders, fetal toxicity, cardiovascular events, bleeding problems, gastrointestinal perforation

Ofev in Mesothelioma Clinical Trials

Ofev has reached phase III in the clinical-trial process. If it continues to show strong results in coming years, the FDA may add it to the standard of care for mesothelioma.

In 2013, cancer centers around the world began to test Ofev for mesothelioma as part of a phase II and III clinical trial called LUME-Meso.

The trial recruited pleural mesothelioma patients with the epithelioid or biphasic cell type. The patients could not be eligible for surgery or have already received chemotherapy.

Participants in the trial were randomized into two groups. One group received standard chemotherapy plus Ofev, while the other group received chemotherapy plus a placebo. LUME-Meso is a double-blind trial, meaning neither patients nor their doctors knew who was receiving a placebo.

By 2016, the combination had proven safe, and the trial has proceeded to phase III. Now its goal is to confirm the combination is more effective than standard chemotherapy alone.

The phase III results are not expected until late 2019, but the phase II findings showed promise. A 2017 article in the Journal of Clinical Oncology detailed the outcomes for 87 participants.

Median survival was 20.6 months for epithelioid patients receiving Ofev, compared to 15.2 months for those receiving placebos.

Patients on Ofev were more likely to experience low white blood cell counts, but serious side effects were actually less common in the experimental group overall.

Though the LUME-Meso trial is no longer recruiting, pleural mesothelioma patients may be eligible for other clinical trials involving Ofev.

Side Effects of Ofev

The most common side effects of Ofev are gastrointestinal problems such as diarrhea, nausea and abdominal pain. Patients should alert their doctor immediately if they experience severe stomach pain, vomiting, sudden dizziness or bleeding problems.

Common Side Effects of Ofev

  • Diarrhea
  • Nausea
  • Abdominal pain
  • Vomiting
  • Liver enzyme elevation
  • Loss of appetite

Rare Side Effects of Ofev

  • Constipation
  • Headaches
  • Weight loss
  • High blood pressure
  • Bruising
  • Joint pain
  • Body aches

Women who are pregnant or breastfeeding should avoid taking Ofev. The drug is also not recommended for people with liver problems.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Writer

Daniel King joined Asbestos.com in 2017. He comes from a military family and attended high school on an Air Force base in Japan, so he feels a close connection to veterans, military families and the many hardships they face. As an investigative writer with interests in mesothelioma research and environmental issues, he seeks to educate others about the dangers of asbestos exposure to protect them from the deadly carcinogen. Daniel holds several certificates in health writing from the Centers for Disease Control and Prevention, and he is a member of the National Association of Science Writers.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Reviewed by placeholder
Medical Review By
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified September 10, 2019

Chat live with a patient advocate now